Equities

Diaceutics PLC

Diaceutics PLC

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Diaceutics PLC is a United Kingdom-based company, which is a provider of technology and solutions. The Company provides pharma and biotech companies with an end-to-end commercialization solution for precision medicine through data analytics, scientific and advisory services enabled by its platform DXRX - The Diagnostics Network. The Company operates through three segments: Insight Solutions (Data), Engagement Solutions (Tech enabled services), and Advisory Services (Professional services). The Company’s DXRX - The Diagnostics Network is a diagnostic commercialization platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories. It provides unrivalled access to multiple pipelines of real-world diagnostic testing data from a global network of laboratories. Its Tech Enabled Services offers clinical testing labs to provide enablement and educational services in novel biomarkers.

  • Revenue in GBP (TTM)21.90m
  • Net income in GBP6.00k
  • Incorporated2005
  • Employees151.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.